No Picture
News

Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries Click here to view original post… […]

No Picture
News

Akebia Announces Otsuka’s Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmaceutical Netherlands B.V. has submitted an initial marketing… Click here to view original post… […]

No Picture
News

Intracellular targets, eye cancer therapy and light-activated skincare: Here’s the latest on biotech IPOs

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. The busy IPO season shows no sign of slowing, with three more biotechs trick-or-treating for their own stock tickers and some sweet raises Thursday. Entrada Therapeutics, Biofrontera Inc. and Aura Biosciences — all… Click here to view original post… […]

No Picture
News

Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a… Click here to view original post… […]

No Picture
News

Alnylam’s John Maraganore isn’t the only CEO to leave his post; CRISPR’s chief commercial officer takes the helm at a protein degradation player

John Maraganore The departure of a number of CEOs is the prevailing theme that kicks off this week’s installment: In a stunner, Alnylam CEO John Maraganore announced that Yvonne Greenstreet will be his successor at the end of the year. Maraganore, the Cambridge, MA biotech’s… Click here to view original post… […]